Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
ESSA Pharma Inc. EPIX
$2.90
-$0.08 (-2.68%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
136557279.00000000
-
week52high
6.06
-
week52low
1.40
-
Revenue
0
-
P/E TTM
-4
-
Beta
2.08892700
-
EPS
-0.71000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 11:00
Описание компании
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Piper Sandler | Overweight | Overweight | 12 мая 2022 г. |
| Oppenheimer | Outperform | Outperform | 17 авг 2021 г. |
| Piper Sandler | Overweight | 04 мар 2021 г. | |
| HC Wainwright & Co. | Buy | Buy | 25 февр 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 11 февр 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Parkinson David Ross | A | 56542 | 3067 | 30 дек 2022 г. |
| Wood David S. | A | 33343 | 8302 | 30 дек 2022 г. |
| Parkinson David Ross | A | 53475 | 21367 | 22 дек 2022 г. |
| BERGER FRANKLIN M | D | 684404 | 34334 | 21 дек 2022 г. |
| BERGER FRANKLIN M | D | 718738 | 37889 | 21 дек 2022 г. |
| BERGER FRANKLIN M | D | 756627 | 43617 | 20 дек 2022 г. |
| BERGER FRANKLIN M | D | 800244 | 50000 | 16 дек 2022 г. |
| BERGER FRANKLIN M | D | 850244 | 50000 | 15 дек 2022 г. |
| BERGER FRANKLIN M | D | 900244 | 32000 | 15 дек 2022 г. |
| BERGER FRANKLIN M | D | 932244 | 25000 | 14 дек 2022 г. |
Новостная лента
ESSA Pharma: One Asset, One Program Company With Little Data
Seeking Alpha
06 февр 2023 г. в 08:28
EPIX is targeting prostate cancer with its lead and only asset EPI-7386. While there's some rationale to the molecule's science, there's not a lot of convincing data yet.
ESSA Pharma: EPI-7386+Xtandi Combination Has Shown Highest Efficacy In Metastatic, Castration-Resistant Prostate Cancer
Seeking Alpha
15 ноя 2022 г. в 22:01
The stock has pulled back from the 2x pop after the recent data of EPI-7386+Xtandi in post-chemotherapy metastatic castration-resistant prostate cancer, mCRPC. The efficacy of the EPI-7386+Xtandi combination in mCRPC beats that of currently approved drugs by a significant margin.
3 Beginner Penny Stocks Trading Mistakes
PennyStocks
30 окт 2022 г. в 11:00
Check these strategies out for buying penny stocks right no The post 3 Beginner Penny Stocks Trading Mistakes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Top Strategies for Making Money With Penny Stocks
PennyStocks
27 окт 2022 г. в 06:00
Use these strategies for making money with penny stocks The post Top Strategies for Making Money With Penny Stocks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Is ESSA Pharma (EPIX) Stock Up 156% Today?
InvestorPlace
26 окт 2022 г. в 12:46
ESSA Pharma (NASDAQ: EPIX ) stock is flying higher on Wednesday following the release of data from a Phase 1/2 study of EPI-7386. EPI-7386 is a drug in development for the treatment of metastatic castration-resistant prostate cancer.